CollPlant posts Q2 2025 results in Form 6-K

CollPlant Biotechnologies Ltd. filed a Form 6-K reporting that it has released its second quarter 2025 financial results and a corporate update.

Rhea-AI Filing Summary

CollPlant Biotechnologies Ltd. filed a Form 6-K reporting that it has released its second quarter 2025 financial results and a corporate update. The company furnished a press release, unaudited condensed consolidated interim financial statements as of June 30, 2025, and an operating and financial review for the same period.

The filing also states that the financial results sections, balance sheet and cash flow information, accompanying consolidated financial statements, and forward-looking statements from these materials are incorporated by reference into CollPlant’s existing Form S-8 and Form F-3 registration statements, making them part of those offerings from the submission date.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did CollPlant Biotechnologies (CLGN) report in this Form 6-K?

CollPlant Biotechnologies reported that it issued its second quarter 2025 financial results and a corporate update. The filing includes a press release, unaudited interim financial statements as of June 30, 2025, and an operating and financial review for the same period.

Which financial period is covered by CollPlant Biotechnologies’ latest disclosure?

The disclosure covers the three- and six-month periods ended June 30, 2025. CollPlant furnished unaudited condensed consolidated interim financial statements and an operating and financial review and prospects relating to this period, together with a detailed press release discussing the quarter.

How is this Form 6-K used in CollPlant Biotechnologies’ existing registration statements?

Key sections of this Form 6-K are incorporated by reference into CollPlant’s Form S-8 and Form F-3 registration statements. This means the financial results, balance sheet and cash flow information, and forward-looking statements now form part of those registration documents from the submission date.

What exhibits are attached to CollPlant Biotechnologies’ August 2025 Form 6-K?

The filing attaches a press release dated August 20, 2025, unaudited condensed consolidated interim financial statements as of June 30, 2025, and an operating and financial review and prospects. It also includes related Inline XBRL instance and taxonomy extension documents and the cover page interactive data file.

Who signed the CollPlant Biotechnologies Form 6-K and in what capacity?

The Form 6-K was signed on behalf of CollPlant Biotechnologies by Eran Rotem. He signed in his roles as Deputy CEO and Chief Financial Officer, indicating executive-level authorization of the submission under the Securities Exchange Act of 1934.

Does this CollPlant Biotechnologies Form 6-K include forward-looking statements?

Yes. The filing specifies that the forward-looking statements section from the attached press release is incorporated by reference. Those statements, together with the financial results and analysis, now also form part of CollPlant’s effective Form S-8 and Form F-3 registration statements.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 08/20/2025 - 08:00 AM Learn about SEC filing dates

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16 UNDER

THE SECURITIES EXCHANGE ACT OF 1934

For the month of August 2025

Commission File Number 001-38370

CollPlant Biotechnologies Ltd.

(Exact name of registrant as specified in its charter)

4 Oppenheimer St, Weizmann Science Park

Rehovot 7670104, Israel

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒        Form 40-F ☐

This Form 6-K, the text under the headings “Three and Six Month-Period Ended June 30, 2025 Financial Results” and “Balance Sheet and Cash Flow”, the accompanying consolidated financial statements and “Forward Looking Statements” of the press release attached to this Form 6-K as Exhibit 99.1, Exhibit 99.2 and Exhibit 99.3 are hereby incorporated by reference into the registrant’s Registration Statements on Form S-8 (File No. 333-229163, 333-248479, 333-263842, 333-271320 and 333-279791) and Form F-3 (File No. 333-238731 and 333-269087), to be a part thereof from the date on which this report is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.

On August 20, 2025, CollPlant Biotechnologies Ltd. (the “Company”) issued a press release entitled “CollPlant Biotechnologies Reports Second Quarter 2025 Financial Results and Provides Corporate Update”. In addition, on the same day, the Company issued condensed consolidated interim financial statements (unaudited) as of June 30, 2025 together with the Company’s Operating and Financial Review and Prospects for the same period.

1

Attached hereto and incorporated by reference herein are the following exhibits:

99.1	Press Release, dated August 20, 2025.
99.2	Condensed Consolidated Interim Financial Statements (unaudited) as of June 30, 2025.
99.3	Operating and Financial Review and Prospects as of June 30, 2025.
101.INS	XBRL Instance Document
101.SCH	Inline XBRL Taxonomy Extension Schema Document
101.CAL	Inline XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF	Inline XBRL Taxonomy Extension Definition Linkbase Document
101.LAB	Inline XBRL Taxonomy Extension Label Linkbase Document
101.PRE	Inline XBRL Taxonomy Extension Presentation Linkbase Document
104	Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	COLLPLANT BIOTECHNOLOGIES LTD.
Date: August 20, 2025	By:	/s/ Eran Rotem
		Name:	Eran Rotem
		Title:	Deputy CEO and Chief Financial Officer

3